How de-extincting dire wolves and woolly mammoths may extend human life
Colossal Biosciences CEO Ben Lamm says bringing extinct species back can contribute to conservation, healthcare and developmental biology.
The claim by Colossal Biosciences CEO Ben Lamm that de-extincting dire wolves and woolly mammoths can contribute to extending human life is an intriguing one, particularly from a financial perspective. This is because the technology and research involved in such a process could have significant spin-off benefits for human healthcare and developmental biology. If successful, this could lead to new markets and investment opportunities in the biotech and pharmaceutical sectors.
The potential for de-extinction technology to drive innovation in healthcare and biology is substantial, and investors are likely to be watching this space closely. The idea that bringing back extinct species could lead to breakthroughs in human medicine is not entirely new, but the application of modern genetic engineering techniques such as CRISPR makes it more feasible than ever before. As such, companies like Colossal Biosciences may attract significant investment if they can demonstrate tangible progress towards their goals.
As this field continues to evolve, it will be important to watch for developments in the regulatory environment and the potential for commercial applications of de-extinction technology. If companies like Colossal Biosciences can successfully harness the power of genetic engineering to bring back extinct species, it could have far-reaching implications for a range of industries, from biotech to conservation. Investors and industry observers will be keen to see whether these efforts can translate into tangible benefits for human health and the environment, and what the financial returns on such investments might be.
Originally reported by cnbc.com. FundingWire adds analysis for finance & markets readers.